SCHEMBL4077151

SCHEMBL4077151

CCCNc1ccccc1[N+](=O)[O-]

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 2/20 0.66
MAPT P10636 6/20 0.60
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HCAR3 P49019 1/20 0.57
ALDH1A1 P00352 5/20 0.57
HTT P42858 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.54
MAPK1 P28482 2/20 0.54
LMNA P02545 2/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 1/20 0.53
PKM P14618 1/20 0.52
CRHBP P24387 1/20 0.52
CRHR2 Q13324 1/20 0.52
GAA P10253 1/20 0.52
CASP7 P55210 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
TP53 P04637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981345 0.90 KAT2B (0.71) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6198859 0.89 KAT2B (0.80) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1170743 0.88 KAT2B (0.69) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL9011355 0.87 KAT2B (0.68) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3477027 0.87 KAT2B (0.68) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11380052 0.87 KAT2B (0.68) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3476402 0.87 KAT2B (0.68) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL7970498 0.87 KAT2B (0.68) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3476711 0.87 KAT2B (0.68) KAT2BMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL7170020 0.85 KAT2B (0.81) KAT2BMAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240231230-A1 COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM NISSAN CHEMICAL CORPORATION (JP) 2024-07-11 US disclosed
WO-2020132582-A1 STING AGONISTS AND USES THEREOF NIMBUS TITAN, INC. (US) 2020-06-25 WO disclosed
CN-110709396-A Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma 伊文蒂瓦公司 2020-01-17 CN disclosed
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2018-07-05 US disclosed
EP-2555623-A1 FLAVIN DERIVATIVES BioRelix, Inc. (US) 2013-02-13 EP disclosed
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20090099164-A1 Phenylaminopropanol Derivatives and Methods of Their Use WYETH (US) 2009-04-16 US disclosed
US-7517899-B2 Phenylaminopropanol derivatives and methods of their use WYETH (US) 2009-04-14 US disclosed
US-20090093469-A1 Phenylaminopropanol Derivatives and Methods of Their Use WYETH (US) 2009-04-09 US disclosed
US-20080009521-A1 Aryl Piperidine Amides HUANG CHARLES Q 2008-01-10 US disclosed
EP-1732887-B1 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) WYETH CORP (US) 2008-01-09 EP disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
US-20050222148-A1 Phenylaminopropanol derivatives and methods of their use WYETH (US) 2005-10-06 US disclosed
WO-2003095441-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2003-11-20 WO disclosed
EP-0332033-A2 N-cyclopropyl anilines and their use in processes for the synthesis of 1-cyclopropyl-quinolone-carboxylic acids and their derivatives BAYER AG (DE) 1989-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099164-A1 Phenylaminopropanol Derivatives and Methods of Their Use PAH, PNMT, COMT KAT2B 3710/4885MAPT 2326/4885NPC1 3723/4885
US-20080009521-A1 Aryl Piperidine Amides BDNF, NTRK2, OPRL1 KAT2B 1261/4885MAPT 898/4885NPC1 514/4885
US-20050222148-A1 Phenylaminopropanol derivatives and methods of their use PAH, PNMT, COMT KAT2B 3710/4885MAPT 2326/4885NPC1 3723/4885
US-20180185362-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH KAT2B 3073/4885MAPT 2388/4885NPC1 609/4885
US-20090093469-A1 Phenylaminopropanol Derivatives and Methods of Their Use PAH, PNMT, COMT KAT2B 3710/4885MAPT 2326/4885NPC1 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.